Three Novel Components of the Human Exosome*

Received for publication, August 21, 2000, and in revised form, October 10, 2000
Published, JBC Papers in Press, November 10, 2000, DOI 10.1074/jbc.M007603200

Rick Brouwer‡, Christine Allmang§, Reinout Raijmakers‡, Yvonne van Aarsen‡, Wilma Vree Egberts‡, Elisabeth Petfalski§, Walther J. van Venrooij‡, David Tollervey§, and Ger J. M. Pruijn‡‡

From the ‡Department of Biochemistry, University of Nijmegen, P. O. Box 9101, NL-6500HB Nijmegen, The Netherlands and the §Institute of Cell and Molecular Biology, Swann Building, King’s Buildings, University of Edinburgh, Mayfield Road, EH9 3JR Edinburgh, Scotland, United Kingdom

The yeast exosome is a complex of 3′ → 5′ exoribonucleases. Sequence analysis identified putative human homologues for exosome components, although several were found only as expressed sequence tags. Here we report the cloning of full-length cDNAs, which encode putative human homologues of the Rrp40p, Rrp41p, and Rrp46p components of the exosome. Recombinant proteins were expressed and used to raise rabbit antiserum. In Western blot experiments, these decorated HeLa cell proteins of the predicted sizes. All three human proteins were enriched in the HeLa cells nucleus and nucleolus, but were also clearly detected in the cytoplasm. Size exclusion chromatography revealed that hRrp40p, hRrp41p, and hRrp46p were present in a large complex. This cofractionated with the human homologues of other exosome components, hRrp4p and PM/Scl-100. Anti-PM/Scl-positive patient sera communoprecipitated hRrp40p, hRrp41p, and hRrp46p demonstrating their physical association. The communoprecipitated complex exhibited 3′ → 5′ exoribonuclease activity in vitro. hRrp41p was expressed in yeast and shown to suppress the lethality of genetic deletion of yeast Rrp41p. We conclude that hRrp40p, hRrp41p, and hRrp46p represent novel components of the human exosome complex.

In both bacteria and eukaryotes, the processing and degradation of many RNA species involves multiprotein complexes (reviewed in Refs. 1–4). The Escherichia coli degradome includes the endoribonuclease E (RNase E), the 3′ → 5′ exonuclease polynucleotide phosphorylase, the DEAD box RNA helicase RhlB, and several additional proteins whose role is unclear (5–7). Related complexes are implicated in RNA processing in chloroplasts and mitochondria (8–10). The yeast exosome contains at least 11 components, which are known or predicted to be 3′ → 5′ exoribonucleases (11, 12). Ten of these (Rrp4p, Rrp40–46p, Mtr3p, and Csl4p) have been demonstrated to be encoded by essential genes. These 10 components were found in both cytoplasmic and nuclear complexes, whereas the nonessential RRP6 gene product was detected only in the nucleus (11, 13).

The 3′ processing of many RNAs is affected by the absence or mutation of exosome components. The nuclear exosome is implicated in the processing of ribosomal RNA (rRNA), spliceosomal small nuclear RNAs, and small nuclear RNAs, as well as the degradation of pre-rRNA spacers and unspliced pre-mRNAs (12–22). The cytoplasmic exosome complex is involved in the 3′ → 5′ pathway of mRNA degradation (22). The activity of the exosome complex may be regulated by cofactors including, for example, the putative ATP-dependent DEVH box RNA helicases Ddb1p and Skl2p (23, 24).

Human cells also contain a multiprotein complex that is related to the yeast exosome (11). This complex, initially designated as the polymyositis/scleroderma (PM/Scl) overlap syndrome particle and herein referred to as the human exosome, was reported to contain 11 (25) to 16 (26) subunits ranging from 20 to 110 kDa. Two proteins of this complex were identified as autoantigens, which are targeted by autoantibodies present in the serum of patients suffering from myositis, scleroderma, or PM/Scl overlap syndrome (27). All tested anti-PM/Scl-positive sera recognize a nuclear protein, known as PM/Scl-100, while some also recognize a protein migrating at about 75 kDa (PM/Scl-75) in SDS-polyacrylamide gel electrophoresis (28–30). PM/Scl-100 and -75 are the human homologues of yeast Rrp6p and Rrp45p, respectively (13, 31). The cloning of five additional human homologues of yeast exosome components has been reported, while ESTs were identified for three further homologues (11, 12, 32–34). However, detailed characterization of human exosome components is limited. The functional conservation has been reported for hRrp4p, hRrp44p/hDis3p, and hCsl4p, and direct evidence for complex formation has been described for hRrp4p and the PM/Scl autoantigens (11).

Here we report the cloning of the human homologues of yeast Rrp40p, Rrp41p (also designated Skl6p), and Rrp46p. Subcellular distribution, communoprecipitation, and in vitro as well as in vitro activity assays show that these three proteins are components of the human exosome.

EXPERIMENTAL PROCEDURES

Isolation of hRrp40p, hRrp41p, and hRrp46p cDNAs—Data homology searches revealed human ESTs, which could be assembled into contigs with apparent homology to yeast exosome components (11). ESTs homologous to yeast Rrp40p (accession numbers AA747302, AA281242, H25417, and AA057832), Rrp41p/Skl6p (accession numbers U46288 and AA129848) and Rrp46p (accession numbers AA428915, AA281132–AF281134.

† To whom correspondence should be addressed. Tel.: 31-24-3616847; Fax: 31-24-3540525; E-mail: g.pruijn@bioch.kun.nl.

‡ The abbreviations used are: PM/Scl, polymyositis/scleroderma; PBS, phosphate-buffered saline; PCR, polymerase chain reaction; VSV, vesicular stomatitis virus G epitope; EST, expressed sequence tag; GST, glutathione S-transferase; ORF, open reading frame; RACE, rapid amplification of cDNA ends; contig, group of overlapping clones.
Novel Human Exosome Components

Table I
Sequences of gene-specific oligonucleotides used in the cloning of hRrp40p, hRrp41p, and hRrp46p

Underlined sequences encode introduced restriction sites to enable cloning into the appropriate expression vectors. Start and stop codons are indicated in bold.

| hRrp40-a | 5'-CAACCAGAACACTGGCAGGATAAG-3' |
| hRrp40-b | 5'-GTCCCAACGATAGAACACGCGCGG-3' |
| hRrp40-c | 5'-CTGCAGTGCAGTCCTTTGAGAC-3' |
| hRrp40-3AS | 5'-CTGATCTCGACGAGCTAACCTTCTGACGACAGGAGG-3' |
| hRrp41-b | 5'-ATATGCGATGCTAAGCTCCG-3' |
| hRrp41-c | 5'-CTCGTGGCGCGGCTAGACACAGC-3' |
| hRrp41-5S | 5'-CTGATTTCAGATGCGGCGGTACCTTCTGACGACAGGAGG-3' |
| hRrp46-a | 5'-CAATCCGGGACCTGCAGGATCAC-3' |
| hRrp46-b | 5'-GGGACGGGAGCCCCACAGAGAAGAG-3' |
| hRrp46-c | 5'-GGCAGGAGGAGCCCCACAGAGAAGAG-3' |
| hRrp46-5S | 5'-CTGATTTCAGATGCGGCGGTACCTTCTGACGACAGGAGG-3' |

AA461395, and AA426493) were selected. Nucleotide sequences of five independent clones of each EST were determined by the dyeoxygenucleotide termination method. Complete (hRRP41) or partial (hRRP40 and hRRP46) open reading frames (ORFs) were identified. To isolate additional cDNAs corresponding to sequences required to complete the ORFs, human teratocarcinoma and placenta cDNA libraries were screened by PCR using gene-specific primers for hRRP40 and hRRP46 (hRRP40-a or hRrp46-a, respectively; see Table I) in combination with λAzL library primers. The largest PCR products were identified by Southern blotting and cloned into the pCR1-TOPO vector (Invitrogen).

Sequence analysis revealed putative start codons for both hRRP40 and hRRP46. The cDNAs isolated from the teratocarcinoma cDNA library were ligated to the coding sequence present in the EST clones. To further investigate the 5' ends of the corresponding mRNAs, a 5' RACE analysis was performed using total human placenta RNA (SMART RACE cDNA amplification kit, CLONTECH). Gene specific primers used for 5' RACE analysis were hRRP40-b, hRrp40-c, hRrp41-c, hRrp46-b, and hRrp46-c. Finally, primers (−5S and −3AS) were designed to introduce restriction sites at the termini of the isolated cDNAs to allow cloning into appropriate expression vectors (see below). The sequences of the oligonucleotides used in the cloning of hRRP40, hRRP41, and hRRP46 are listed in Table I.

Complementation Experiments—To test for complementation of the yeast conditional alleles GAL::rrp40, GAL::rrp41, and GAL::rrp46, the cDNAs isolated from the teratocarcinoma cDNA library were ligated to the coding sequence present in the EST clones.

Transient Transfection of HEp-2 Cells and Indirect Immunofluorescence—For transfection, hRrp40, hRrp41, and hRrp46 cDNAs were cloned into the pcDNA3 vector (Promega), which contained a sequence element encoding the vesicular stomatitis virus G epitope (VSV) to allow expression of N-terminally and/or C-terminally VSV-tagged proteins. HEp-2 cells were grown to 80% confluence by standard tissue culture techniques in Dulbecco's modified Eagle's medium (Life Technologies, Inc.) containing 10% fetal calf serum. Approximately 2 × 10⁶ cells were transfected with 10–20 μg of DNA in 800 μl of Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum by electroporation, which was performed at 270 V and 850 microfarads using a Gene Pulser II (Bio-Rad). After transfection, cells were seeded onto coverslips and cultured for 24 h. Cells were washed twice with PBS, fixed with methanol for 5 min at −20 °C, briefly rinsed in acetone, air-dried, and stored at −20 °C until use.

For indirect immunofluorescence, fixed cells were subsequently incubated for 1 h at room temperature with an affinity-purified mouse anti-VSV tag monoclonal antibody (Roche Molecular Biochemicals) and subsequently with fluorescein isothiocyanate-conjugated swine anti-mouse Ig (Dako Immunoglobulins) and fluorescein isothiocyanate-conjugated swine anti-rabbit Ig (Dako Immunoglobulins). All antibodies were diluted 50-fold in PBS. Cells were mounted with PBS/glycerol containing Mowiol, and bound antibodies were visualized by fluorescence microscopy.

Preparation of HeLa Cell Extracts—Cytoplasmic and nuclear HeLa cell extracts were prepared according to the modification of the Dignam procedure essentially as described by Wahle et al. (37).

Immunoprecipitation—Immunoprecipitations were essentially performed as described previously (38). Per immunoprecipitation, 10 μl of patient serum or 20 μl of rabbit serum was coupled to 10 μl of protein A-agarose (Bioyam) and extract of 2.5 × 10⁶ HeLa cells was used. For the Western blotting, the immunoprecipitates were heated for 5 min in SDS sample buffer and fractionated by SDS-polyacrylamide gel electrophoresis (39).

Size Exclusion Chromatography—Nuclear and cytoplasmic extract of 75 × 10⁶ HeLa cells was fractionated by automated liquid chromatography (BioLogic, Bio-Rad) using the Superdex 200 HR 10/30 column (Amersham Pharmacia Biotech) in a buffer containing 10 mM Hepes-KOH, pH 7.9, and 100 mM KCl at 0.5 ml/min. Thirty samples of ~330 μl were collected, and proteins were immediately precipitated by the addition of four volumes of acetone. After overnight incubation at −70 °C, pellets were collected by centrifugation at 13,000 × g for 30 min. Air-dried pellets were solubilized in SDS sample buffer, and proteins were analyzed by Western blotting (20% of each fraction). To estimate complex sizes, gel filtration standards (Bio-Rad), including thyroglobulin (670 kDa), bovine IgG (158 kDa), chicken ovalbumin (44 kDa), equine myoglobin (17 kDa), and vitamin B₁₂ (1.35 kDa), were analyzed as described above.

In Vitro Exonuclease Assay—Immunoprecipitations were performed as described above. After removal of nonbinding material, immune complexes bound to the protein A-agarose beads were washed twice with buffer A (10 mM Tris-HCl, pH 7.5, 50 mM KCl, 5 mM MgCl₂, 1 mM Na₃VO₄). Substrate solution (32P-labeled substrate in buffer A) was added to the protein A beads, and the suspension was incubated at 37 °C with gentle agitation. Formamide loading buffer was added to samples taken at regular intervals and immediately frozen until analysis. Samples were analyzed by denaturing polyacrylamide gel electrophoresis followed by autoradiography. Strutures, transcribed in vitro...
Cloning of Human Homologues of Yeast Rrp40p, Rrp41p/Ski6p, and Rrp46p—Full length cDNAs encoding human homologues of the S. cerevisiae Rrp40p, Rrp41p/Ski6p, and Rrp46p (open reading frames YOL142w, YGR195w, and YGR095c, respectively) were generated based upon EST clones, cDNA-specific PCR fragments isolated from a teratocarcinoma cDNA library, and 5′ RACE products obtained from human placental RNA (Fig. 1). These sequence data have been submitted to the DDBJ/EMBL/GenBank® data bases under accession numbers AF281132, AF281133, and AF281134. From the cDNAs, hRrp40p, hRrp41p, and hRrp46p have predicted molecular masses of 31 kDa (275 amino acids), 27 kDa (245 amino acids), and 26 kDa (235 amino acids), respectively. The data in Table III show that the predicted protein sequences of hRrp40p, hRrp41p, and hRrp46p are relatively well conserved to the S. cerevisiae (Sc) homologues, and clear homologues are also present in M. musculus (Mm), C. elegans (Ce), and S. pombe (Sp). hRrp41p and hRrp46p are both homologous to E. coli RNase PH (11, 12, 31) and therefore show homology to each other, whereas hRrp40p is not significantly homologous to hRrp41p or hRrp46p.

Two genomic sequences for hRRP46 are present in the data base; a complete sequence on chromosome 19 and a partial sequence (accession no. L08634) corresponding to nucleotides 23 to +150 of the isolated hRRP46 cDNA clone. A T/C polymorphism is evident in these sequences, resulting in an amino acid substitution (methionine/threonine) at position 5 of hRrp46p. Both types of cDNA were obtained from the 5′ RACE analyses, and ESTs exist with each nucleotide. In the studies described below, the cDNA clone encoding threonine at position 5 was used. Polymorphism was also evident in the region 5′ to the ORF, with an in frame upstream stop codon present in L08634, but not in the chromosome 19 sequence. In the latter, the ORF could potentially extend 33 amino acids further 5′. However, no cDNA that extends beyond 23 nucleotides of the 5′-untranslated region was isolated and the extended ORF sequence would be in poorer agreement with the molecular weight predicted from the observed gel migration of the protein from HeLa cell lysates, compared with that synthesized in E. coli. Therefore, we believe that the cDNA used encodes the full-length protein. An EST with an internal truncation in the hRrp46p ORF was also found, presumably as a consequence of alternative splicing, that leads to a frameshift at Gly-85 and truncation of the polypeptide.

Two EST clones encoding a possible splicing variant of hRrp46p (accession nos. AA282142 and H25417) were identified, and the same sequence is listed as apoptosis-related protein PNAS-3 mRNA (accession no. AF228933). These lack an internal region of the ORF leading to frameshift at Gln-158 and truncation of the polypeptide.

hRrp41p Encodes a Functional Homologue of Yeast Rrp41p/Ski6p—To test whether hRrp40p, hRrp41p, or hRrp46p can complement mutations in the corresponding yeast genes, the full-length cDNAs were cloned into yeast expression vectors under the control of the strong constitutive NOP1 promoter (see “Experimental Procedures”). The constructs were transformed into yeast strains in which the endogenous genes were subject to GAL regulation; strains GAL::rrp40, GAL::rrp41, and GAL::rrp46. Western blotting (data not shown) confirmed that each of the human proteins was well expressed. In plate assays, the growth inhibition of the GAL::rrp41 strain on glucose medium was efficiently suppressed by expression of hRrp41p (Fig. 2), showing it to be the functional homologue of Rrp41p/Ski6p. The expression of hRrp40p or hRrp46p did not support the growth of GAL::rrp40 or GAL::rrp46 strains, respectively, indicating that the human proteins are unable to perform all of the essential functions of their yeast homologues.

Detection of hRrp40p, hRrp41p, and hRrp46p in Human Cells—The cloned cDNAs were expressed as His-tagged and/or GST-tagged polypeptides using the bacterial and baculovirus expression systems. In each case this resulted in the synthesis of proteins with gel mobilities close to those expected for the predicted molecular weights. The recombinant proteins were purified by Ni2+ or glutathione affinity chromatography and used to raise rabbit antisera, designated H70 (anti-hRrp40p), H71 (anti-hRrp41p), and H73 (anti-hRrp46p). All sera recognized the corresponding recombinant His-tagged protein on Western blots (Fig. 3, A–C, lanes Ag). The reactivity of all antisera with all three recombinant proteins was analyzed by Western blotting. Purification of the baculovirus-expressed hRrp46p might, in principle, have led to the copurification of the endogenous insect exosome complex; moreover, hRrp46p and hRrp41p are homologous (see Table III). However, none of the anti-sera showed detectable cross-reactivity.

To demonstrate that hRrp40p, hRrp41p, and hRrp46p are expressed in HeLa cells, Western blots containing total HeLa cell extracts were probed with the rabbit antisera (Fig. 3, A–C, lanes T). Although the sera recognized more than one protein in the total cell extract, prominent species (indicated by arrowheads) were detected in each case that migrated somewhat faster than the corresponding recombinant His-tagged proteins
Novel Human Exosome Components

Table III

|          | Mn* | Ce* | Sp* | Sc* | hRrp40p | hRrp41p | hRrp46p |
|----------|-----|-----|-----|-----|---------|---------|---------|
| hRrp40p  | 88/91* | 34/56 | 31/50 | 30/46 | 100/100 | 12/26 | 18/28 |
| hRrp41p  | 96/97 | 44/62 | 42/57 | 35/54 | 12/26 | 100/100 | 28/43 |
| hRrp46p  | 89/93 | 31/46 | 29/46 | 38/42 | 18/28 | 28/43 | 100/100 |

* Polyopeptide encoded by contig assembled with mouse (*M. musculus*) ESTs.

Western blots were probed with the rabbit sera H70 (Fig. 3A), H71 (Fig. 3B), and H73 (Fig. 3C). hRrp40p, hRrp41p, and hRrp46p were each detected in both the nuclear (N) and cytoplasmic (C) fraction, with lower yields in the cytoplasm (C). Weaker signals were seen in residual nuclear material after salt extraction (R). A similar distribution was found for hRrp4p (Fig. 3D). In contrast, PM/Scl-100 was recovered almost entirely in the nuclear fraction (Fig. 3E).

To confirm the subcellular localization of hRrp40p, hRrp41p, and hRrp46p, polypeptides carrying N-terminal and C-terminal VSV tags were expressed in HEp-2 cells. Indirect immunofluorescence of cells transfected with these constructs showed that all of these VSV-tagged proteins were strongly enriched in the nucleoli (Fig. 4). In addition, a weaker diffuse staining was widely distributed in the nucleoplasm and cytoplasm. Indirect immunofluorescence using the rabbit antisera H70 and H73 also resulted in prominent staining of the nucleoli of HEp-2 cells. Rabbit antisera H71 did not give signals in indirect immunofluorescence (data not shown).

We conclude that hRrp40p, hRrp41p, and hRrp46p are present in both the cytoplasm and nucleus, with the highest concentration in the nucleus.

hRrp40p, hRrp41p, and hRrp46p Are Part of the PM/Scl Complex—The previously identified components of the human exosome (hRrp4p, PM/Scl-75, and PM/Scl-100) cosegregated in a large complex on glycerol gradient centrifugation of HeLa cell lysates (11). To determine whether hRrp40p, hRrp41p, and hRrp46p are associated with complexes of similar size, HeLa cell extracts were fractionated by size exclusion chromatography.

Cytoplasmic and nuclear extracts were prepared from 75 × 10⁶ cells and separately fractionated by chromatography on a Superdex 200 column. For each extract, 30 fractions were collected and analyzed by Western blotting with rabbit antisera H70, H71, H73, anti-hRrp4p, and anti-PM/Scl-100 (Fig. 5). These analyses revealed that hRrp40p, hRrp41p, and hRrp46p are associated with relatively large complexes in the cytoplasmic (Fig. 5A) and nuclear (Fig. 5B) extracts. All three proteins cofractionated with PM/Scl-100 and hRrp4p in both the cytoplasmic and nuclear extracts.

To estimate the size of the complexes, gel filtration standards were fractionated using the same conditions. In the cytoplasmic extract, the exosome components peaked in fractions three and four corresponding to a molecular mass of ~700 kDa. In the nuclear extract, all exosome proteins analyzed except PM/Scl-100 showed a broader distribution over fractions 3–11, corresponding to estimated molecular masses of ~250–700 kDa.

(Fig. 3, A–C, compare lanes Ag and T). Immunoprecipitation experiments (see below) confirmed that these correspond to the hRrp40p, hRrp41p, and hRrp46p.

We conclude that hRrp40p, hRrp41p, and hRrp46p are present in HeLa cell lysates and show gel mobilities close to those expected for their predicted molecular weights.

Subcellular Localization of hRrp40p, hRrp41p, and hRrp46p—In yeast, 10 out of 11 known components are associated with both the cytoplasmic and the nuclear forms of the exosome, while Rrp6p is detected only in the nucleus (11). Western blotting experiments showed that hRrp4p and PM/Scl-75 are components of both nuclear and cytoplasmic complexes in human cells, while PM/Scl-100 (the homologue of Rrp6p) appears to be solely nuclear (11).

To determine the subcellular distribution of hRrp40p, hRrp41p, and hRrp46p, HeLa cells were separated into three fractions: cytoplasmic extract (C), nuclear extract (N), and the nuclear material retained after salt extraction (R). The material of an equal number of cells (5 × 10⁶ cells) from each fraction was used for Western blotting. As controls for the fractionation, we analyzed the largely cytoplasmic histidyl-tRNA synthetase (Jo-1, Fig. 3F), the nuclear DNA topoisomerase I (DNA Topo I, Fig. 3G), and the nuclear matrix-associated protein lamin B (Fig. 3H). The positions of migration are indicated by arrowheads. These results confirmed that the cells were fractionated as expected.

Western blots were probed with the rabbit sera H70 (Fig. 3A), H71 (Fig. 3B), and H73 (Fig. 3C). hRrp40p, hRrp41p, and hRrp46p were each detected in both the nuclear (N) and cytoplasmic (C) fraction, with lower yields in the cytoplasm (C). Weaker signals were seen in residual nuclear material after salt extraction (R). A similar distribution was found for hRrp4p (Fig. 3D). In contrast, PM/Scl-100 was recovered almost entirely in the nuclear fraction (Fig. 3E).
The peak of PM/Scl-100 was limited to fractions 3 and 4, suggesting association with only the higher molecular weight complexes. Similar results were obtained following fractionation of nuclear extracts by glycerol gradient centrifugation, which showed cosedimentation of hRrp40p and hRrp41p with hRrp4p and the PM/Scl autoantigens (data not shown).

Coimmunoprecipitation experiments were performed to confirm the physical association of hRrp40p, hRrp41p, and hRrp46p with the known human exosome components. Five anti-PM/Scl-positive patient sera were used to immunoprecipitate the exosome complex from a HeLa cell nuclear extract; three anti-PM/Scl-negative sera served as controls (Fig. 6A). The immunoprecipitates were analyzed by Western blotting using the rabbit antisera H70, H71, and H73. hRrp40, hRrp41, and hRrp46 were each immunoprecipitated by the anti-PM/Scl-positive sera, but not by the control sera. Although the rabbit antisera showed reactivity with several proteins present in the total nuclear extract (Fig. 6A, lanes i), each rabbit antiserum consistently stained only one protein in the immunoprecipitates. In each case the gel mobility corresponded with the predicted molecular weight, confirming that these represent the cognate proteins.

In the converse experiments, sera H70, H71, and H73 were used for immunoprecipitation and the coprecipitation of PM/Scl autoantigens was detected with two anti-PM/Scl patient sera, Lun7 and Lun36. Sera H70 and H73 each coimmunoprecipitated PM/Scl-100 from a nuclear HeLa cell extract (Fig. 6B, right panel). In addition, both patient sera stained several smaller proteins that were immunoprecipitated by H70 and H73 from the nuclear extract, which may represent other components of the PM/Scl particle. Neither pre-immune sera (PI lanes) precipitated the PM/Scl-100 autoantigen or any of the smaller proteins. PM/Scl-100 was also coimmunoprecipitated at low levels from a cytoplasmic extract by sera H70 and H73 (Fig. 6B, left panels). Serum H71 failed to precipitate PM/Scl-100 (Fig. 6B) and also failed to decorate the nucleoli of HEp-2 cells in immunofluorescence microscopy (data not shown). This may be due either to inaccessibility of hRrp41p in the complex or to the inability of the antibodies to recognize native hRrp41p.

We conclude that hRrp40p, hRrp41p, and hRrp46p are present in a complex containing the known human exosome components, PM/Scl-100 and hRrp4p.

Exoribonuclease Activity of the Complexes Containing hRrp40p, hRrp41p, and hRrp46p—The human exosome complex was immunoprecipitated from a HeLa cell extract using rabbit antisera H70, H71, and H73 or anti-PM/Scl-positive patient serum R212. The pre-immune rabbit sera and a pool of...
10 normal human sera served as negative controls. Associated exoribonuclease activity was assayed in vitro with an internally labeled 37-nucleotide single-stranded RNA substrate. The immunoprecipitates obtained with rabbit antisera H70 and H73 and patient serum R212 exhibited ribonuclease activity, with progressive disappearance of the RNA substrate and the accumulation of the labeled end-product (Fig. 7, left panel, lanes 2–4 and 8–13). Analysis of the reaction products by thin layer chromatography revealed that the accumulating end products are nucleoside monophosphates consistent with exo-nucleolytic degradation of the substrate (data not shown). Omission of phosphate from the buffer used in this assay, which has been shown to affect the activity of yeast Rrp41p/Ski6p (12), did not significantly inhibit the reaction (data not shown). Immunoprecipitates obtained with rabbit antiserum H71 (Fig. 7, right panel) did not show nucleolytic activities. The similar patterns of reaction products seen with H70 and H73 indicate that the complexes immunoprecipitated by each serum are related.

When the substrate was 3'-labeled with 32P, incubation with the immunoprecipitates obtained with sera H70, H73, or R212 resulted in the disappearance of the RNA substrate without detectable intermediate products. We conclude that the immunoprecipitated complexes exhibit 3' → 5' exonuclease activity. Removal of the 3' phosphate group, inherently introduced by the [32P]pCp labeling procedure, resulted in a slightly enhanced reaction (data not shown) indicating a preference for a 3'-hydroxyl residue, as seen for the yeast exosome (12).

These results show that hRrp40 and hRrp46 are associated with a complex displaying 3' → 5' exoribonuclease activity in vitro. We conclude that these proteins are indeed novel human exosome components.

DISCUSSION

We have characterized three novel human polypeptides, hRrp40p, hRrp41p, and hRrp46p, encoded by cDNAs that were isolated on the basis of homology to the yeast exosome components Rrp40p, Rrp41p/Ski6p, and Rrp46p, respectively (11). Western blotting experiments using rabbit antisera raised against each of the recombinant proteins showed that HeLa cells express proteins of the predicted molecular weights. Consistent with data previously obtained for human exosome components, all three proteins are present in both the cytoplasm and nucleus, with nucleolar enrichment. The novel proteins were shown to be part of a large complex cofractionating with hRrp4p and PM/Scl-100. The physical association with the PM/Scl autoantigens was confirmed by coimmunoprecipitation. Functional assays demonstrated that the complexes containing hRrp40p and hRrp46p display 3' → 5' exoribonuclease activity in vitro. Moreover, expression of hRrp41p in yeast is able to support the growth of cells depleted of yeast Rrp41p/Ski6p. We conclude that hRrp40p, hRrp41p, and hRrp46p are novel components of the human exosome complex.

Subcellular Localization of hRrp40p, hRrp41p and hRrp46p—Consistent with previous data using anti-PM/Scl positive patient sera, hRrp40p, hRrp41p, and hRrp46p were shown by indirect immunofluorescence to be enriched in the nucleolus. However, subcellular fractionation showed that hRrp40p, hRrp41p, and hRrp46p are present in both nuclear and cytoplasmic fractions, as is hRrp4p (11). Salt extraction released most of the nuclear hRrp40p, hRrp41p, and hRrp46p,
but a substantial amount of each protein was retained. The release of DNA topoisomerase I indicated that the high salt extraction was efficient. We speculate that the extracted and retained fractions represent nucleoplasmic and nucleolar pools of the exosome, respectively. Diffusely distributed nucleoplasmic and cytoplasmic populations are presumably less visible in immunofluorescence than is the nucleolar population.

The distribution of the human exosome components is similar to that previously seen for yeast Rrp4p and Rrp43p (11, 40). The yeast exosome is implicated in RNA processing reactions in the nucleolus (pre-rRNA processing and spacer degradation), nucleoplasm (pre-small nucleolar RNA and pre-small nuclear RNA processing and pre-mRNA degradation) and cytoplasm (mRNA degradation) (12–23), and the distribution observed for exosome components presumably reflects these functions. The similarities in the distribution patterns, and the complementation of yeast mutants by the human proteins, make it likely that the human exosome will carry out many or all of the same functions.

The yeast exosome is implicated in the degradation of unspliced pre-mRNAs (18, 22) and might therefore influence the outcome of alternative splicing events. The identification of cDNAs that apparently result from alternative splicing of hRRP40 and hRRP46 therefore raises interesting possibilities for autogenous regulation.

Characterization of the Complex Containing hRrp40p, hRrp41p, and hRrp46p—Immunoprecipitation with anti-PM/Scl-positive patient sera, using metabolically labeled human cell extracts, indicated that the PM/Scl complex consists of at least 11 proteins (25, 26). The estimated molecular masses of the proteins found in these studies were 110, 90, 80, 39, 37, 33, 30, 27, 26, 22, and 20 kDa. Comparison of these molecular masses with those of the proteins characterized in the present study suggested that hRrp40, hRrp41 and hRrp46 correspond to the 30-, 27-, and 26-kDa proteins, respectively.

Size exclusion chromatography of the exosome complex in a HeLa cell extract, indicated that the cytoplasmic complex has a molecular mass of \(700\) kDa. The nuclear complex gave a broad distribution between 250 and 700 kDa. These complex sizes were estimated based upon the separation of gel filtration standards. However, this fractionation may not be dependent solely on the mass of the complex, but may also reflect its...
structure relative to the protein size markers. It is also unclear whether the size distribution of the nuclear exosome reflects the existence of multiple, heterogeneous complexes or whether it is due to instability of the complex. The size of the human exosome complex estimated by size exclusion chromatography was larger than previously estimated from glycerol gradient centrifugation (12), presumably reflecting differences in the physical basis of the separation techniques.

The complexes immunoprecipitated with anti-hRrp40p (H70) or anti-hRrp46p (H73) showed very similar in vitro activities. In each case, both processive and distributive activities are suggested by the data. A distributive exonuclease activity removes one (or a few) nucleotide(s) before dissociating from the substrate. In consequence, its activity is “distributed” over the entire substrate population, which is therefore progressively shortened in approximate synchrony. Such an activity would be consistent with the shortening of the RNA population near the top of the gel in the H70 and, particularly, H73 lanes in Fig. 7 (lanes 2–4 and 8–10, respectively). In contrast, binding of a processive exonuclease to the molecule of substrate results in its rapid degradation to a short residual fragment, at which point the RNA is too short for the enzyme to bind. In consequence, a fraction of the substrate is rapidly shortened, while most of the substrate in untouched. Such an activity may be seen in the early time points of using the H70 and H73 immunoprecipitates shown in Fig. 7.

Acknowledgments—We thank Dr. I. Lundberg for providing patient sera and Dr. E. Hurt for providing pNOPPATA1L. We also thank J. Koenderink and J. Vogelzangs for their contribution to the baculovirus expression.

REFERENCES

1. Carpousis, A. J., Vanzo, N. F., and Raynal, L. C. (1999) Trends Genet. 15, 24–28
2. Van-Hoof, A., and Parker, R. (1999) Cell 99, 347–350
3. Hayes, R., Kudla, J., and Gruss, W. (1999) Trends Biochem. Sci. 24, 199–202
4. Margossian, S. P., and Butow, R. A. (1996) Trends Biochem. Sci. 21, 392–396
5. Blum, E., Py, B., Carpousis, A. J., and Higgins, C. F. (1997) Mol. Microbiol. 26, 387–398
6. Micaak, A., Kaberdin, V. R., Wei, C. L., and Lin, C. S. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 3865–3869
7. Py, B., Higgins, C. F., Kriscic, H. M., and Carpousis, A. J. (1996) Nature 381, 169–172
8. Hayes, R., Kudla, J., Schuster, G., Gabay, L., Maliga, P., and Gruss, W. (1999) EMBO J. 18, 1132–1141
9. Min, J., and Zassenhaus, H. P. (1993) J. Bacteriol. 175, 6245–6253
10. Min, J., Haurie, R. M., and Zassenhaus, H. P. (1993) J. Biol. Chem. 268, 7350–7357
11. Allmang, C., Petfsalski, E., Podtelejnikov, A., Mann, M., Tollervey, D., and Mitchell, P. (1999) Genetics 153, 2148–2155
12. Mitchell, P., Petfsalski, E., Shvechenko, A., Mann, M., and Tollervey, D. (1997) Cell 91, 457–466
13. Briggs, M. W., Burckhardt, K. T., and Butler, J. S. (1998) J. Biol. Chem. 273, 13255–13263
14. Zanchin, N. I., and Goldfarb, D. S. (1999) Nucleic Acids Res. 27, 1283–1288
15. Allmang, C., Kufel, J., Chanfreau, G., Mitchell, P., Petfsalski, E., and Tollervey, D. (1999) EMBO J. 18, 3599–356
16. Mitchell, P., Petfsalski, E., and Tollervey, D. (1996) Genes Dev. 10, 502–513
17. Van-Hoof, A., Lennertz, P., and Parker, R. (2000) Mol. Cell. Biol. 20, 441–452
18. Burckhardt, K. T., and Butler, J. S. (2000) Mol. Cell. Biol. 20, 640–646
19. Kufel, J., Allmang, C., Chanfreau, G., Petfsalski, E., Lafontaine, D., and Tollervey, D. (2000) Mol. Cell. Biol. 20, 5415–5425
20. Allmang, C., Mitchell, P., Petfsalski, E., and Tollervey, D. (2000) Nucleic Acids Res. 28, 1684–1691
21. Benard, L., Carroll, K., Val, R. C., and Wickner, R. B. (2000) Mol. Cell. Biol. 18, 2688–2696
22. Bousquet-Antonelli, C., Presutti, C., and Tollervey, D. (2000) Cell 102, 765–773
23. Jacobs, J. S., Anderson, A. R., and Parker, R. P. (1998) EMBO J. 17, 1497–1506
24. de la Cruz, J., Kressser, D., Tollverve, D., and Linder, P. (1998) EMBO J. 17, 1129–1140
25. Reiner, G., Schee, U., Peters, J. M., and Tan, E. M. (1986) J. Immunol. 137, 3802–3808
26. Gelpi, C., Alguero, A., Angeles, M. M., Vidal, S., Juarez, C., and Rodriguez, S. J. (1996) J. Exp. Med. 183, 1–84
27. Reichlin, M., Maddison, P. J., Targoff, I., Bunch, T., Arnett, F., Sharp, G., Treadwell, E., and Tan, E. M. (1984) J. Clin. Immunol. 4, 40–44
28. Aldercreutz, P., Chang, K. K., and Tan, E. M. (1991) J. Exp. Med. 173, 941–952
29. Bluthner, M., and Bautz, F. A. (1992) J. Exp. Med. 176, 973–980
30. Ge, Q., Frank, M. B., O’Brien, C., and Targoff, I. N. (1992) J. Clin. Invest. 90, 559–570
31. Mian, I. S. (1997) Nucleic Acids Res. 25, 3187–3195
32. Shiomi, T., Fukushima, K., Suzuki, N., Nakashima, N., Noguchi, E., and Nishimoto, T. (1998) J. Biochem. (Tokyo) 123, 883–890
33. Baker, R. E., Harris, K., and Zhang, K. (1998) Genetics 149, 73–85
34. Williams, J. M., Chen, C. G., Zhu, L., and Rest, R. F. (1998) Mol. Microbiol. 27, 171–186
35. Frangioni, J. V., and Nes, B. G. (1993) Anal. Biochem. 210, 179–187
36. Harlow, E., and Lane, D. (1988) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
37. Wahl, E., and Keller, W. (1994) in RNA Processing: A Practical Approach (Higgins, S. J., and Ham, B. D., eds) Vol. II, pp. 1–34, Oxford University Press, New York
38. Brouwer, R., Vree, E. W., Jongen, P. H., van Engelen, B. G., and van Venrooij, W. J. (1998) Arthritis Rheum. 41, 883–890
39. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 11724
40. Zanchin, N. I., and Goldfarb, D. S. (1999) Mol. Cell. Biol. 19, 1518–1526
41. Lafontaine, D., and Tollervey, D. (1996) Nucleic Acids Res. 24, 3469–3471
Three Novel Components of the Human Exosome
Rick Brouwer, Christine Allmang, Reinout Raimakers, Yvonne van Aarssen, Wilma
Vree Egberts, Elisabeth Petfalski, Walther J. van Venrooij, David Tollervey and Ger J. M.
Pruijn

J. Biol. Chem. 2001, 276:6177-6184.
doi: 10.1074/jbc.M007603200 originally published online November 10, 2000

Access the most updated version of this article at doi: 10.1074/jbc.M007603200

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 39 references, 16 of which can be accessed free at
http://www.jbc.org/content/276/9/6177.full.html#ref-list-1